Brokers Set Expectations for OCUL FY2027 Earnings

Key Points

• HC Wainwright projects FY2027 EPS of ($1.51) and rates OCUL a Buy with a $21 price target, while the Street consensus is a "Moderate Buy" with an average target of about $23.78 (12 Buys, 1 Hold, 1 Sell).
• Most recent quarter showed EPS of ($0.29) that beat estimates by $0.04, but revenue missed at $13.25M (down 22.4% YoY) and the company reported a deeply negative net margin (~−558%) and ROE (~−71%).
• Shares opened at $9.71 with a $2.13B market cap (52‑week range $6.23–$16.44); insiders have sold roughly 185,731 shares (~$1.65M) in the past 90 days and institutions own about 59% of the stock.

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Ocular Therapeutix in a report issued on Wednesday, May 6th. HC Wainwright analyst Y. Chen anticipates that the biopharmaceutical company will post earnings of ($1.51) per share for the year. HC Wainwright has a "Buy" rating and a $21.00 price objective on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($1.29) per share.

Several other research analysts have also weighed in on OCUL. William Blair restated an "outperform" rating on shares of Ocular Therapeutix in a research note on Monday, March 2nd. Weiss Ratings restated a "sell (d-)" rating on shares of Ocular Therapeutix in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of Ocular Therapeutix from a "hold" rating to a "sell" rating in a report on Saturday, February 28th. Chardan Capital reaffirmed a "buy" rating and set a $21.00 target price on shares of Ocular Therapeutix in a report on Wednesday, February 18th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $30.00 target price on shares of Ocular Therapeutix in a report on Wednesday. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $23.78.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock opened at $9.71 on Thursday. The firm has a market capitalization of $2.13 billion, a PE ratio of -6.65 and a beta of 0.93. The company's 50-day moving average is $9.07 and its 200-day moving average is $10.53. Ocular Therapeutix has a fifty-two week low of $6.23 and a fifty-two week high of $16.44. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. The firm had revenue of $13.25 million for the quarter, compared to analyst estimates of $16.13 million. Ocular Therapeutix had a negative net margin of 558.24% and a negative return on equity of 71.22%. The company's revenue was down 22.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.29) EPS.

Insider Activity at Ocular Therapeutix

In other news, insider Nadia Waheed sold 3,510 shares of the company's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $7.74, for a total transaction of $27,167.40. Following the completion of the sale, the insider owned 314,907 shares of the company's stock, valued at approximately $2,437,380.18. This represents a 1.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jeffrey S. Heier sold 3,057 shares of the company's stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $8.28, for a total transaction of $25,311.96. Following the sale, the insider directly owned 323,368 shares of the company's stock, valued at approximately $2,677,487.04. This trade represents a 0.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 185,731 shares of company stock worth $1,653,407 in the last 90 days. Corporate insiders own 2.30% of the company's stock.

Hedge Funds Weigh In On Ocular Therapeutix

A number of institutional investors have recently added to or reduced their stakes in OCUL. Steward Partners Investment Advisory LLC increased its position in Ocular Therapeutix by 124.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 1,242 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new position in Ocular Therapeutix during the 4th quarter worth approximately $31,000. Hilton Head Capital Partners LLC increased its position in Ocular Therapeutix by 30.4% during the 1st quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 1,053 shares in the last quarter. Atlas Capital Advisors Inc. acquired a new position in Ocular Therapeutix during the 4th quarter worth approximately $61,000. Finally, KBC Group NV acquired a new position in Ocular Therapeutix during the 4th quarter worth approximately $78,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.